Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt106PMID 23524864PMCID PMC3690906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

  2012cited by this paper
• Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

  2012cited by this paper
• Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer

  2012cited by this paper
• Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

  2012cited by this paper
• HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment

  2012cited by this paper
• HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

  2012cited by this paper
• Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

  2011cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• HER-2 amplification is highly homogenous in gastric cancer.

  2010cited by this paper
• Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

  2009cited by this paper
• Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Diagnostic Pathology BioMed Central Methodology

  2009cited by this paper
• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  2009cited by this paper
• Meta‐analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer

  2009cited by this paper
• HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

  2008cited by this paper
• Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

  2008cited by this paper
• Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus

  2007cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cited by this paper
• Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.

  2007cited by this paper
• HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer

  2006cited by this paper
• Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").

  2006cited by this paper
• Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

  2006cited by this paper
• Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.

  2006cited by this paper
• Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

  2006cited by this paper
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

  2005cited by this paper
• Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.

  2004cited by this paper
• Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

  2004cited by this paper
• Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.

  2003cited by this paper
• HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells

  2003cited by this paper
• Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

  2002cited by this paper
• Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

  2001cited by this paper
• c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

  2000cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  1999cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

  1997cited by this paper
• Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

  1995cited by this paper
• erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection.

  1994cited by this paper
• Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.

  1994cited by this paper
• Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

  1993cited by this paper
• Relationship of C‐erbB‐2 protein expression and gene amplification to invasion and metastasis in human gastric cancer

  1993cited by this paper
• Overexpression of c‐erbB‐2 protein in gastric cancer. Its correlation with long‐term survival of patients

  1993cited by this paper
• Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma

  1992cited by this paper
• c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.

  1992cited by this paper
• Expression of C‐erbB‐2 oncoprotein in gastric carcinoma. Immunoreactivity for C‐erbB‐2 protein is an independent indicator of poor short‐term prognosis in patients with gastric carcinoma

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study

  2025cites this paper
• Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues

  2024cites this paper
• HER2 in Gastric Cancer: A Comprehensive Analysis Combining Meta-Analysis and DCE-MRI Radiomics

  2024cites this paper
• [Assessment of HER2 status of carcinomas of various localizations].

  2023cites this paper
• Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study

  2023cites this paper
• Clinicopathological Significance and Prognostic Role of Her2neu Protein Expression in Patients with Carcinoma Stomach: A Prospective Study from Northern India

  2023cites this paper
• Assessment of HER2 in Gastric Type Endocervical Adenocarcinoma and its Prognostic Significance.

  2023cites this paper
• How cells sense and integrate information from different sources.

  2023cites this paper
• Natural Products for Esophageal Cancer Therapy: From Traditional Medicine to Modern Drug Discovery

  2022cites this paper
• The current state of molecular profiling in gastrointestinal malignancies

  2022cites this paper
• Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer

  2022cites this paper
• Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma

  2021cites this paper
• A Novel Six-Gene-Based Prognostic Model Predicts Survival and Clinical Risk Score for Gastric Cancer

  2021cites this paper
• Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer

  2021cites this paper
• Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China

  2021cites this paper
• Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer

  2021cites this paper
• A Reliable and Standardizable Differential PCR and qPCR Methodology Assesses HER2 Gene Amplification in Gastric Cancer

  2021cites this paper
• Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population

  2020cites this paper
• Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

  2020cites this paper
• A four-DNA methylation signature as a novel prognostic biomarker for survival of patients with gastric cancer

  2020cites this paper
• Integrated immune gene expression signature and molecular classification in gastric cancer: New insights

  2020cites this paper
• Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy

  2019cites this paper
• Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis

  2019cites this paper
• Clinicopathological Significance of HER2/neu Expression in Gastric Carcinoma

  2019cites this paper
• Improving Clinical Trial Design in Gastrointestinal Oncology

  2019cites this paper
• Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond.

  2019cites this paper
• Current and future therapies for targeting HER2 mutations in gastrointestinal cancer

  2018cites this paper
• Progress of preoperative and postoperative radiotherapy in gastric cancer

  2018cites this paper
• Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?

  2018cites this paper
• Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation

  2018cites this paper
• Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches

  2018cites this paper
• Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

  2018cites this paper
• At the intersection of Diabetes and Cancer: the role of angiogenesis and inflammation

  2017cites this paper
• Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

  2017cites this paper
• Plasma microRNA‐based signatures to predict 3‐year postoperative recurrence risk for stage II and III gastric cancer

  2017cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

  2017cites this paper
• Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

  2017cites this paper
• Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer

  2017cites this paper
• An Update on Randomized Clinical Trials in Gastric Cancer.

  2017cites this paper
• Prognostic Value of Pretreatment HER2 Status in Gastric Cancer Patients Treated with Postoperative Chemoradiotherapy

  2017cites this paper
• Novel Targeted Therapies for Esophagogastric Cancer.

  2017cites this paper
• CEP3 and CEP17 DNA probe potential in the genetic diagnosis and prognostic prediction of esophageal squamous cell cancer.

  2016cites this paper
• HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

  2016cites this paper
• Gastric biomarkers: a global review

  2016cites this paper
• The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

  2016cites this paper
• Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer

  2016cites this paper
• CEP 3 and CEP 17 DNA probe potential in the genetic diagnosis and prognostic prediction of esophageal squamous cell cancer

  2016cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

  2016cites this paper
• Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.

  2016cites this paper
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

  2016cites this paper
• Concordance Rate between HER2 Immunohistochemistry and in Situ Hybridization in Gastric Carcinoma: Systematic Review and Meta-Analysis

  2016influential citation
• Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

  2016cites this paper
• Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

  2016cites this paper
• HER 2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline

  2016cites this paper
• Advances in the Management of Gastric and Gastroesophageal Cancers

  2016cites this paper
• Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

  2015cites this paper
• Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.

  2015cites this paper
• Molecular biomarkers in gastric cancer.

  2015cites this paper
• What to expect from HER-2 directed therapies in advanced gastric cancer?

  2015cites this paper
• Systemic therapy and targeted agents in advanced esophageal cancer

  2015cites this paper
• HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison

  2015cites this paper
• Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.

  2015cites this paper
• Adjuvant therapy for gastric cancer: what have we learned since INT0116?

  2015cites this paper
• Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

  2015cites this paper
• Resected gastric cancer with D2 dissection: advances in adjuvant chemoradiotherapy and radiotherapy techniques

  2015cites this paper
• Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

  2014cites this paper
• Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma

  2014cites this paper
• Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer

  2014cites this paper
• The potential for targeting HER2 therapeutically in esophageal cancer – a grasp at straws?

  2014cites this paper
• HER2 positive gastric and gastroesophageal adenocarcinoma; An Irish tertiary center experience

  2014cites this paper
• MicroRNA signature for HER2-positive breast and gastric cancer.

  2014cites this paper
• Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer

  2014cites this paper
• Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.

  2014cites this paper
• New directions in perioperative management of locally advanced esophagogastric cancer.

  2014cites this paper
• Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care

  2013cites this paper
• Gastroesophageal cancer: focus on epidemiology, classification, and staging.

  2013cites this paper
• Oncology ScandGastrointestinal Cancers

  2013cites this paper
• Expresión de Her2/neu en carcinoma gástrico en el área metropolitana de Bucaramanga en el periodo 2006 a 2009

  2013cites this paper
• Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy

  2013cites this paper
• 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer.

  2013cites this paper
• Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices

  2013cites this paper
• Oncology scan--gastrointestinal cancers.

  2012cites this paper